Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Last day of trading for Solidcore Resources shares will be September 23

8/30/24 POLY

Novoship reports for 6 months of 2024 by IFRS

8/30/24 NOMP

Solidcore shareholders were offered to sell shares

8/30/24 POLY

Nauka-Svyaz reported for 6 months of 2024 by IFRS

8/30/24 NSVZ

Moscow Exchange to add 16 more shares to OTC with CCs

8/30/24 MOEX

Nefaz reported for 6 months of 2024 by IFRS

8/30/24 NFAZ

OMZ reported for 6 months of 2024 by IFRS

8/30/24 OMZZP

VTB's profit in July decreased by 42%

8/30/24 VTBR

Globaltrans has no plans to resume dividend payments

8/30/24 GLTR

Globaltrans reported for 6 months of 2024

8/30/24 GLTR